FOCUS ON EUROPE

EMA Recommends Erlotinib as Maintenance for NSCLC

The European Medicines Agency announced March 19 that it has issued a positive opinion on the chemotherapy drug erlotinib as a maintenance treatment for patients with locally advanced or metastatic non-small...

Everolimus Too Costly, Survival Data Insufficient, Says NICE

The clinical effectiveness agency for England and Wales has published draft guidance opposing everolimus as a second-line treatment for advanced renal cell carcinoma, the most common form of kidney cancer,...

NICE Draft Opposes Pemetrexed for Metastatic Non-Small-Cell Lung Cancer

The clinical effectiveness agency for England and Wales has issued draft guidance opposing use of pemetrexed as a maintenance treatment for people with locally advanced or metastatic non-small-cell lung...

NICE Draft Backs Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia

Rituximab would be authorized to treat relapsed or refractory chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide under a draft guideline published by the clinical effectiveness...